The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes.
Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown
to reduce production and deposition of fat in the liver in animal experiments. There is
little published evidence that this is so in Asian patients with type 2 diabetes. The
investigators designed this pilot study to determine if use of empagliflozin for 6 months in
patients with type 2 diabetes can improve scan, blood marker and biopsy features of NAFLD.